1. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117–2128. https://doi.org/10.1056/NEJMoa1504720
2. EMPA-KIDNEY Collaborative Group; Herrington, W. G.; Staplin, N.; et al. (2023). Empagliflozin in patients with chronic kidney disease. The New England Journal of Medicine, 388(2), 117–127. https://doi.org/10.1056/NEJMoa2204233
3. Sanjari et al. (2025) – Effect of empagliflozin on weight in patients with prediabetes and diabetes.Sanjari, M., Hadavizadeh, M., Sadeghi, N., & Naghibzadeh-Tahami, A. (2025). Effect of empagliflozin on weight in patients with prediabetes and diabetes. Scientific Reports, 15(1). https://doi.org/10.1038/s41598-024-83820-7